SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer (Q35112055)
Jump to navigation
Jump to search
scientific article
Language | Label | Description | Also known as |
---|---|---|---|
English | SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer |
scientific article |
Statements
1 reference
SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer (English)
1 reference
1 reference
Mary-Ellen Taplin
1 reference
Mari Nakabayashi
1 reference
Ming Yang
1 reference
Wanling Xie
1 reference
Elahe Mostaghel
1 reference
Lillian Werner
1 reference
Tong Sun
1 reference
Mark Pomerantz
1 reference
Matthew Freedman
1 reference
Robert Ross
1 reference
Meredith Regan
1 reference
Nima Sharifi
1 reference
William Douglas Figg
1 reference
Steven Balk
1 reference
Gwo-Shu Mary Lee
1 reference
23 May 2011
1 reference
1 reference
29
1 reference
18
1 reference
2565-2573
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference